Rocket Pharmaceuticals (RCKT) Net Income towards Common Stockholders (2014 - 2026)

Rocket Pharmaceuticals has disclosed Net Income towards Common Stockholders across 13 years of filings, most recently posting -$47.6 million for Q1 2026.

• Net Income towards Common Stockholders for Q1 2026 came in at -$47.6 million, up 22.4% year-over-year; the trailing twelve-month figure through Mar 2026 was -$209.4 million (up 18.85% YoY), and the FY2025 annual result was -$223.1 million, up 13.77% from the prior year.
• Net Income towards Common Stockholders came in at -$47.6 million for Q1 2026 at Rocket Pharmaceuticals, down from -$42.5 million in the prior quarter.
• In the past five years, Net Income towards Common Stockholders ranged from a high of -$42.5 million in Q4 2025 to a low of -$69.6 million in Q2 2024.
• The 5-year median for Net Income towards Common Stockholders is -$60.3 million (2024), against an average of -$58.6 million.
• Across the five-year window, Net Income towards Common Stockholders sank 57.57% in 2022 and advanced 29.49% in 2025, its largest moves.
• Rocket Pharmaceuticals' Net Income towards Common Stockholders stood at -$66.7 million in 2022, then advanced by 10.59% to -$59.7 million in 2023, then slipped by 1.12% to -$60.3 million in 2024, then rose by 29.49% to -$42.5 million in 2025, then dropped by 11.89% to -$47.6 million in 2026.
• The last three Net Income towards Common Stockholders figures came in at -$47.6 million (Q1 2026), -$42.5 million (Q4 2025), and -$50.3 million (Q3 2025), per Business Quant data.